Mercks Investigational Zilovertamab Vedotin in Combination With R-CHP Demonstrates Complete Response Rate of 100 percent at 1.75 mgkg Dose in Phase 2 Trial of Previously Untreated Patients With Diffuse Large B-Cell Lymphoma
| TNBIX Fund | USD 20.02 0.10 0.50% |
Slightly above 62% of 1290 Smartbeta's investor base is looking to short. The analysis of overall sentiment of trading 1290 Smartbeta Equity mutual fund suggests that many investors are alarmed at this time. 1290 Smartbeta's investing sentiment can be driven by a variety of factors including economic data, 1290 Smartbeta's earnings reports, geopolitical events, and overall market trends.
1290 |
RAHWAY, N.J., December 08, 2024--Merck , known as MSD outside of the United States and Canada, today announced the first presentation of data from the Phase 2 waveLINE-007 trial evaluating zilovertamab vedotin, Mercks investigational antibody drug conjugate that targets receptor tyrosine kinase-like orphan receptor 1 , in combination with cyclophosphamide, doxorubicin and prednisone plus rituximab for the treatment of patients with previously untreated diffuse lar
Read at finance.yahoo.com
 |
1290 Smartbeta Fundamental Analysis
We analyze 1290 Smartbeta's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of 1290 Smartbeta using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of 1290 Smartbeta based on its fundamental data. In general, a quantitative approach, as applied to this mutual fund, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Three Year Return
Three Year Return Comparative Analysis
1290 Smartbeta is currently under evaluation in three year return among similar funds. Tree Year Return shows the total annualized return generated from holding a fund or ETFs for the last three years. The return measure includes capital appreciation, losses, dividends paid, and all capital gains distributions. This return indicator is considered by many investors to be solid measures of fund mid-term performance.
1290 Smartbeta Equity Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with 1290 Smartbeta mutual fund to make a market-neutral strategy. Peer analysis of 1290 Smartbeta could also be used in its relative valuation, which is a method of valuing 1290 Smartbeta by comparing valuation metrics with similar companies.
Peers
1290 Smartbeta Related Equities
| TNHIX | 1290 High | 0.23 | ||||
| TNUIX | 1290 Unconstrained | 0.36 | ||||
| TNBAX | 1290 Smartbeta | 0.45 | ||||
| TNBRX | 1290 Smartbeta | 0.50 | ||||
| TNVIX | 1290 Gamco | 0.84 |
Other Information on Investing in 1290 Mutual Fund
1290 Smartbeta financial ratios help investors to determine whether 1290 Mutual Fund is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in 1290 with respect to the benefits of owning 1290 Smartbeta security.
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon |